Is VEGF a key target of cotinine and other potential therapies against Alzheimer disease?

dc.creatorEcheverria V.
dc.creatorBarreto G.E.
dc.creatorÁvila-Rodriguez M.
dc.creatorTarasov V.V.
dc.creatorAliev G.
dc.date.accessioned2020-09-02T22:17:28Z
dc.date.accessioned2022-11-08T20:18:50Z
dc.date.available2020-09-02T22:17:28Z
dc.date.available2022-11-08T20:18:50Z
dc.date.created2020-09-02T22:17:28Z
dc.date.issued2017
dc.identifier14, 11, 1155-1163
dc.identifier15672050
dc.identifierhttps://hdl.handle.net/20.500.12728/4448
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5142906
dc.languageen
dc.publisherBentham Science Publishers B.V.
dc.subjectAlzheimer disease
dc.subjectAmyotrophic lateral sclerosis
dc.subjectAngiogenesis
dc.subjectCotinine
dc.subjectDementia
dc.subjectDepression
dc.subjectNeurodegeneration
dc.subjectNicotinic receptors
dc.subjectTobacco
dc.subjectVEGF
dc.subjectcotinine
dc.subjectneuroprotective agent
dc.subjectvasculotropin A
dc.subjectAlzheimer disease
dc.subjectanimal
dc.subjecthuman
dc.subjectmetabolism
dc.subjectAlzheimer Disease
dc.subjectAnimals
dc.subjectCotinine
dc.subjectHumans
dc.subjectNeuroprotective Agents
dc.subjectVascular Endothelial Growth Factor A
dc.titleIs VEGF a key target of cotinine and other potential therapies against Alzheimer disease?
dc.typeReview


Este ítem pertenece a la siguiente institución